ClinicalTrials.gg

Program

Valacyclovir

Also written as “Valacyclovir hydrochloride”, “Valaciclovir” and “Valacyclovir Hydrochloride”.

Its studies are mostly in Herpes Genitalis · Herpes Zoster · Herpes Simplex · Prostatic Neoplasms · Lung Neoplasms, led by 7 companies.

Furthest: phase 4, since Mar 18, 200423 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline110 open or runningphase 4since Mar 18, 2004Nov 2, 1999none ahead
Viatris30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jun 2, 2010Jun 2, 2010none ahead
Hikma Pharmaceuticals20 open or runningno phasesince May 25, 2010May 25, 2010none ahead
Sun Pharmaceutical Industries20 open or runningno phasesince Oct 15, 2010Oct 15, 2010none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jun 21, 2010Jun 21, 2010none ahead
aRigen Pharmaceuticals10 open or runningphase 2since Apr 1, 2008Apr 1, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 2, 1999.

  1. May 11, 2000Phase 3 study in Herpes SimplexGlaxoSmithKline · NCT00005663 · United States, Canada
  2. Mar 18, 2004Phase 4 study in Herpes GenitalisGlaxoSmithKline · NCT00079911 · 7 enrolled · United States, Australia, Hong Kong
  3. Jun 30, 2005Phase 4 study in Herpesviridae InfectionsGlaxoSmithKline · NCT00116844 · 73 enrolled · United States
  4. Sep 8, 2005Phase 4 study in Herpes GenitalisGlaxoSmithKline · NCT00158860 · 384 enrolled · United States, Argentina, Brazil and more
  5. Sep 9, 2005Phase 3 study in ChickenpoxGlaxoSmithKline · NCT00169416 · 43 enrolled
  6. Feb 24, 2006Phase 1 study in Herpes SimplexGlaxoSmithKline · NCT00297206 · 36 enrolled · United States, Chile, South Africa
  7. Mar 21, 2006Phase 4 study in Herpes LabialisGlaxoSmithKline · NCT00306293 · 70 enrolled · United States
  8. Jun 21, 2006Phase 4 study in Virus DiseasesGlaxoSmithKline · NCT00343278 · 18 enrolled
  9. Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00650494, NCT00649974, NCT00649870
  10. Apr 1, 2008aRigen Pharmaceuticals's first study: phase 2 study in Herpes ZosterNew to aRigen PharmaceuticalsaRigen Pharmaceuticals · NCT00652184 · 300 enrolled · United States
  11. May 25, 2010Hikma Pharmaceuticals's first studies: 2 no phase studies in Herpes ZosterNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01132729, NCT01132716
  12. Jun 2, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01136538, NCT01136525
  13. Jun 21, 2010Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT01149499, NCT01149460
  14. Oct 15, 2010Sun Pharmaceutical Industries's first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01222910, NCT01222897

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human herpesvirus 1 DNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT01222910Healthy · India–CompletedSun Pharmaceutical IndustriesMay 200936
NCT01222897Healthy · India–CompletedSun Pharmaceutical IndustriesMay 200940
NCT01149499Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200560
NCT01149460Healthy · Canada1CompletedTeva Pharmaceutical IndustriesSep 200436
NCT01136538Healthy · India1CompletedDr. Reddy's LaboratoriesFeb 200734
NCT01136525Healthy · India1CompletedDr. Reddy's LaboratoriesMar 200741
NCT01132729Herpes Zoster · United States–CompletedHikma PharmaceuticalsSep 200648
NCT01132716Herpes Zoster · United States–CompletedHikma PharmaceuticalsSep 200648
NCT00652184Herpes Zoster · United States2UNKNOWNaRigen PharmaceuticalsJun 2009300
NCT00650494Healthy · United States1CompletedViatrisAug 200566
NCT00649974Healthy · United States1CompletedViatrisMay 200528
NCT00649870Healthy · United States1CompletedViatrisMay 200526
NCT00343278Virus Diseases4CompletedGlaxoSmithKlineAug 200518
NCT00306293Herpes Labialis · United States4CompletedGlaxoSmithKlineNov 27, 200670
NCT00297206Herpes Simplex · United States, Chile, South Africa1CompletedGlaxoSmithKlineFeb 28, 200736
NCT00169416Chickenpox3CompletedGlaxoSmithKlineAug 200543
NCT00158860Herpes Genitalis · United States, Argentina, Brazil and more4CompletedGlaxoSmithKlineJul 26, 2006384
NCT00116844Herpesviridae Infections · United States4CompletedGlaxoSmithKlineJan 10, 200673
NCT00079911Herpes Genitalis · United States, Australia, Hong Kong4TerminatedGlaxoSmithKlineOct 15, 20047
NCT00005663Herpes Simplex · United States, Canada3UNKNOWNGlaxoSmithKline
NCT00002404Herpes Simplex–CompletedGlaxoSmithKline30
NCT00002084Herpes Simplex · United States–CompletedGlaxoSmithKline
NCT00002000Herpes Simplex · United States–CompletedGlaxoSmithKline

How it is read

Names in the registry

  • “Valacyclovir hydrochloride”, 6 entries
  • “Valacyclovir”, 4 entries
  • “Valaciclovir”, 4 entries
  • “Valacyclovir Hydrochloride”, 4 entries
  • “Valacyclovir Hydrochloride Tablets 1000 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.